

ASX RELEASE



ASX Code: ESE

ESENSE-LAB APPROVED FOR CANNABIS PERMIT

Life science company **eSense-Lab Ltd** ("**eSense**" or the "**Company**") (**ASX:ESE**) is pleased to announce that it has been approved by the Israeli Ministry of Health for a Cannabis permit.

Under the Dangerous Drugs Ordinance [New Version], 5733 – 1973 Cannabis is a substance that is defined as a "dangerous drug". Therefore, any activities related to Cannabis and its derivatives are closely regulated by the Medical Cannabis Unit, including any research and development ("R&D") on Cannabis strains and their derivatives. The Medical Cannabis Unit is the authorized body in the Ministry of Health that issues patients with permits to use cannabis for medical purposes, in accordance with the governmental procedures, to assess authorization and to issue appropriate permits to those engaged in the field of cannabis and to investigators and various research bodies that wish to carry out studies of cannabis and cannabinoids.

Under the terms of the permit, eSense Lab will be able to perform R&D on Cannabis strains available in Israel, perform comparative research and utilize the Company's proprietary technology in evaluation of the composition of Cannabis strains and replicating them with natural non-cannabis terpenes. Additional applications are now being submitted to approve the Company, under the current permit, to import Cannabis strains from other countries.

The commercial importance of the approval for the above-mentioned permit, is that the Company, will be able to improve its terpene formulations so that they are more closely matched with the original cannabis product, in terms of flavour and aroma, but still avoid the problematic legal status of psychoactive cannabinoid compounds such as THC and CBD. By having direct access to the cannabis plant strains, the Company will be able to increase its formulation portfolio, which will be offered directly to various manufacturers interested in implementing cannabis aroma and/or flavour in their products.

In addition the permit provides tools for future activities where the terpenoid fingerprint of specific medical strains to treat pain, epilepsy, chronic inflammation, or any other type of disease known to be treated by Cannabis, can be characterized, formulated and implemented in association with cannabinoids for medical treatment.

The immediate significance of the permit approval is the opportunities open to the Company to perform adaptation and improvement of its terpene formulations for use in the various commercial industries interested in implementing Cannabinoid properties without the THC and CBD compounds.

Commenting on the above announcement, eSense's CEO Mr. Haim Cohen, stated: *"I'm pleased to announce to the market that after a lengthy due diligence process with the Medical Cannabis Unit, eSense has received its permit to perform research and development activities on actual Cannabis strains."*

"While a lengthy process, it is an important milestone in the Company's efforts in establishing itself as a non-psychoactive alternative to many of the Cannabis properties, that are being sought after for implementation in a variety of products from e-cigarettes, cosmetics, beverages and more."

"This permit, so sought-after, will allow the Company to further perfect its terpene formulations, allowing us to supply a product that can mimic Cannabinoids, without any of the psychoactive compounds that are still illegal for commerce in many countries and businesses."

"Additionally, this permit allows the Company to promote further research into the medical and nutraceutical applications for Cannabinoids, replacing them with our terpene formulations".

"This important milestone in our technological efforts, allows eSense, with its proprietary knowledge and formulations, to be used in additional, lucrative markets."

"I look forward to informing the market on the continuation of our activities and successes".

FOR FURTHER INFORMATION:

Company Secretary

Ian Pamensky

+61 414 864 746

ian@cfo2grow.com.au

About eSense-Lab

eSense-Lab Ltd (ASX: ESE) is a life sciences company specialising in the commercialisation of the phytochemical profiling of plants. The Company combines genetics, mRNA, protein expression and phytochemical profiles to generate a comprehensive model of rare or high value plants. eSense-Lab can then use this model to 'reverse engineer' a terpene profile, which is a naturally occurring formulation of different individual terpenes which together account for many of the plant's health and medical benefits, whilst also exactly replicating the flavour, fragrance and other desired characteristics of the targeted plant, at a more sustainable and cheaper cost

To learn more about eSense-Lab, visit www.esense-lab.com